Clinical Trials Logo

Clinical Trial Summary

The whole blood Thrombelastograph (TEG®) Platelet Mapping™ assay measures clot strength, maximal amplitude (MA), reflecting maximal platelet function, and detects the reduction in platelet function, presented as percentage inhibition, by both aspirin and clopidogrel. A study reported that the TEG® can be used as routine monitoring of the variability in ADP receptor inhibition and of antiplatelet therapy. Therefore, using TEG Platelet Mapping assay, we could find out the perioperative clopidogrel responsiveness of the patients with ACS undergoing OPCAB.

The purpose of this study is to determine whether the rate of the major adverse cardiac events (MACE, a combined endpoint of MI, revascularization and cardiac death) is higher in the patients with high degree of clopidogrel resistance, who are scheduled to undergo the OPCAB due to ACS.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02184884
Study type Observational
Source Yonsei University
Contact
Status Completed
Phase
Start date July 2014
Completion date March 30, 2020

See also
  Status Clinical Trial Phase
Terminated NCT00385138 - Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. Phase 3
Completed NCT01944800 - Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome Phase 4
Completed NCT02290080 - Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction by Biomarkers Phase 3
Completed NCT02286544 - Effects of Oxygen Treatment on Mechanisms Involved in Ischemia-reperfusion Injury: A Pilot Study in Healthy Volunteers Phase 1
Completed NCT01405287 - Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT Phase 2
Completed NCT00767507 - Maintenance of Platelet Inhibition With Cangrelor Phase 2
Completed NCT03672097 - Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI) Phase 4
Completed NCT00399880 - Improving Medication Adherence Through Graphically Enhanced Interventions in Acute Coronary Syndromes N/A
Completed NCT02430493 - Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients N/A
Completed NCT01994577 - Optimum Troponin Cutoffs for ACS in the ED
Completed NCT00313300 - Safety Study of Apixaban in Recent Acute Coronary Syndrome Phase 2
Completed NCT02244710 - EndoTic - Endothelium and Ticagrelor N/A
Active, not recruiting NCT04090281 - Implementing Precision Medicine Approaches to Guide Anti-platelet Selection Phase 4
Active, not recruiting NCT03581578 - VITROS Immunodiagnostic Products hs Troponin I
Recruiting NCT04116931 - OPTImal Management of Antithrombotic Agents: OPTIMA-5 Phase 4
Not yet recruiting NCT06449274 - RESTORE Imaging: an OCT-IVUS Imaging Substudy of RESTORE Trial N/A
Completed NCT02171065 - PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial. N/A
Completed NCT00855257 - Assessment of Endothelial Vasomotricity After Treatment by Nicotinic Acid in Acute Coronary Syndrome Phase 3
Completed NCT02733341 - The Effect of IV Cangrelor and Oral Ticagrelor Study Phase 4
Completed NCT00932100 - A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome Phase 2